Who are Alpha1-Proteinase Inhibitor's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alpha1-proteinase-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Alpha1-Proteinase Inhibitor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alpha1-Proteinase Inhibitor (Alpha1-Proteinase Inhibitor) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor (protein replacement therapy). Area: Pulmonology / Respiratory.

marketed Protease inhibitor (protein replacement therapy) Neutrophil elastase (indirect target via AAT inhibition) Pulmonology / Respiratory Biologic Live · refreshed every 30 min

Target snapshot

Alpha1-Proteinase Inhibitor (Alpha1-Proteinase Inhibitor) — Baxalta now part of Shire. Alpha1-proteinase inhibitor (AAT) replaces deficient or dysfunctional alpha-1 antitrypsin protein to protect lung tissue from enzymatic degradation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alpha1-Proteinase Inhibitor TARGET	Alpha1-Proteinase Inhibitor	Baxalta now part of Shire	marketed	Protease inhibitor (protein replacement therapy)	Neutrophil elastase (indirect target via AAT inhibition)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor (protein replacement therapy) class)

Baxalta now part of Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alpha1-Proteinase Inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/alpha1-proteinase-inhibitor. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab